Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2958892 | 0.98 | CHRNA7 (0.35) | CHRNA7KCNJ6KCNJ5KCNJ3IDO1 | |
| SCHEMBL2952198 | 0.91 | CSF1R (0.39) | CHRNA7KCNJ6KCNJ5KCNJ3TDO2 | |
| SCHEMBL2959282 | 0.90 | CHRNA7 (0.35) | CHRNA7KCNJ6KCNJ5KCNJ3CSF1R | |
| Lithium Ion SCHEMBL1266477 | 0.90 | CHRNA7 (0.35) | CHRNA7KCNJ6KCNJ5KCNJ3IDO1 | |
| SCHEMBL1267006 | 0.89 | DHODH (0.44) | MAPTDHODHMEN1KMT2APOLB | |
| SCHEMBL1266727 | 0.87 | DHODH (0.34) | CHRNA7KCNJ6KCNJ5KCNJ3IDO1 | |
| Ammonia Solution, Strong SCHEMBL2956251 | 0.86 | MAPT (0.41) | CHRNA7IDO1TDO2MAPTMEN1 | |
| SCHEMBL1267284 | 0.86 | ADORA2B (0.35) | CHRNA7KCNJ6KCNJ5KCNJ3CSF1R | |
| SCHEMBL5668001 | 0.85 | KHK (0.34) | CHRNA7KCNJ6KCNJ5KCNJ3MAPT | |
| SCHEMBL5667681 | 0.84 | HTR1F (0.36) | CHRNA7KCNJ6KCNJ5KCNJ3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | CHRNA7 3397/4885KCNJ6 2059/4885KCNJ5 2601/4885 |
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | MAPKAPK2, MAP3K6, MAP3K12 | CHRNA7 3757/4885KCNJ6 1476/4885KCNJ5 2079/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | CHRNA7 1693/4885KCNJ6 2051/4885KCNJ5 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.